A. A. Skvortsov

A. A. Skvortsov

Auto-generated profile, based on publicly available information

A. A. Skvortsov

Chazov National Medical Research Center of Cardiology

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Kardiologiia
Verified
Journal Article
Open access
PDF file
NVNasezhda Vinogradova
Nasezhda Vinogradova
VBV. S. Berestovskaya
V. S. Berestovskaya
ZBZ. N. Blankova
Z. N. Blankova
TVT. V. Vavilova
T. V. Vavilova
NGN. V. Gomyranova
N. V. Gomyranova
STS. N. Tereshchenko
S. N. Tereshchenko
The burden of heart failure (HF) has been increasing worldwide in recent decades. Early diagnosis of HF based on the outpatient measurement of natriuretic peptide (NP) concentration will allow timely initiation of the treatment and reducing the incidence of adverse outcomes in HF. Unfortunately, the frequency of NP testing remains low worldwide. At the online expert meeting held on March 15, 2024, the features of the N-terminal pro-brain natriuretic peptide (NT-proBNP) test (Elecsys proBNP by Roche) were discussed along with the interpretation of test results and presentation of results in laboratory reports. The experts addressed the features of the Elecsys proBNP test in patients with suspected HF in various clinical scenarios (chronic and acute HF). The limits of clinical decision for the NT-proBNP test were established depending on the clinical scenario. Changes in the Elecsys proBNP test results depending on the comorbidities were addressed. The experts suggested ways to optimize the format of the Elecsys proBNP test result reports in the Russian Federation, which will accelerate the implementation of the test in clinical practice and optimize the management of HF patients.

28 June 2021 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSN. B. Shlevkov
N. B. Shlevkov
AGA. Zh. Gasparyan
A. Zh. Gasparyan
AZA. A. Zhambeev
A. A. Zhambeev
HSH. F. Salami
H. F. Salami
EGE. V. Guseva
E. V. Guseva
SGS. P. Golitsyn
S. P. Golitsyn
Background: According to numerous studies, from 30% to 50% of patients with chronic heart failure (CHF) are resistant to cardiac resynchronization therapy (CRT) and cardiac contractility modulation (CCM), despite their careful selection in accordance with current guidelines. It is of interest to study neurohormones characterizing myocardial (NT-proBNP) and fibrosis (sST2) as potential additional markers of CHF patients' “response” to CRT and CCM.Aim: To evaluate the potential to use NT-proBNP and sST2 biomarkers in CHF patients combined with transthoracic echocardiography (Echo) and contrast magnetic resonance imaging (MRI) parameters of the heart to predict a positive response to CRT and CCM devices.Materials and methods: The study included 51 patients (41 men, 10 women) aged 58 ± 12 years (26 to 79 years) with ischemic heart disease post acute myocardial infarction (n = 22) or non-ischemic cardiomyopathy (n = 29), left ventricle (LV) ejection fraction (EF) < 35%, and CHF II–III NYHA functional class despite ≥ 3 months of optimized medical therapy. The patients were assessed by serum biomarkers NT-proBNP and sST2 measurements, transthoracic Echo, and contrast- enhanced cardiac MRI. After the diagnostic assessment, CRT defibrillators (CRT-D) were implanted to 39 patients and CCM to 12 patients. After prospective follow-up of the patients for 18 to 24 months, predictors of the response to each device type were analyzed in univariate, multivariate, and ROC analysis.Results: The response to CRT-D was found in 21 (54%) patients, to CCM in 7 (58%) patients. Multivariate analysis showed the following predictors of the response of patients to CRT-D were: 1) sST2 < 50 ng/mL, 2) NT-proBNP < 3900 pg/mL, 3) < 3 LV segments with fibrosis (by MRI) and 4) anteroposterior dimension of the left atrium < 4.8 cm (by Echo). Any 2 of these 4 characteristics made it possible to predict the response to CRT with an accuracy of 87% (sensitivity 90%, specificity 83%). The predictors of the response to CCM were: 1) sST2 < 30 ng/ml, 2) LV end diastolic diameter < 78 mm (Echo), 3) age < 56 years, 4) body mass index < 27 kg/m2. Any 2 of these 4 characteristics predicted the positive response to CCM with an accuracy of 92% (sensitivity 86%, specificity 100%).Conclusion: The preoperative sST2 level was the only universal marker of the response to either CRT (< 50 ng/mL) or CCM (< 30 ng/mL) devices in CHF patients with reduced LVEF. The results indicate the potential for improved efficacy of these devices with their earlier implantation after the onset of the heart disease, as well as provided that maximal control CHF in these patients has been achieved.


14 April 2025 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
ONO.YU. Narusov
O.YU. Narusov
MUMuksinova
Muksinova
ASA.A. Skvortsov
A.A. Skvortsov
TST.V. Sharf
T.V. Sharf
VMV.P. Masenko
V.P. Masenko
STS.N. Tereshchenko
S.N. Tereshchenko
Objective. To assess the risk of cardiovascular complications in patients with heart failure and reduced ejection fraction (HFrEF) depending on sST2 and NT-proBNP concentrations at discharge and in long-term follow-up after treatment of acute decompensated heart failure (ADHF). Material and methods. The study included 132 patients hospitalized for decompensated HFrEF due to coronary artery disease, dilated cardiomyopathy, and hypertension. Serum sST2 and NT-proBNP were analyzed at baseline, upon discharge, after 30, 90 and 180 days. The follow-up period was one year. We analyzed cardiovascular events including episodes of decompensation/hospitalization for HF and cardiovascular mortality. Results. The risk of cardiovascular events decreases within a year after discharge in case of serum sST2 and NT-proBNP at discharge <29.3 ng/mL (AUC 0.631±0.050, 95% CI: 0.534–0.728, p=0.010) and 2647 pg/mL (AUC 0.615±0.050, 95% CI: 0.518–0.713, p=0.024), respectively. Serum sST2≤23.4 ng/ml (AUC 0.746±0.051, 95% CI: 0.647–0.846, p<0.001) or decrease by ≥34.3% (20.8; 48.2), as well as NT-proBNP≤1132 pg/ml (AUC 0.757±0.049, 95% CI: 0.660–0.853, p<0.001) or decrease by ≥38.9% within 6 months was associated with lower risk of cardiovascular complications. This risk was high without simultaneous decrease of both biomarkers (OR=6.583; 95% CI 3.448–12.569, p<0.001). Conclusion. To reduce the risk of cardiovascular complications, it is necessary to achieve simultaneous decrease of sST2 ≤23.4 ng/ml or by ≥34.3% and NT-proBNP ≤1132 pg/ml or by ≥38.9%.

27 December 2023 in Kardiologiia
Verified
Journal Article
Open access
PDF file
MMM. D. Muksinova
M. D. Muksinova
ONO. Yu. Narusov
O. Yu. Narusov
ASA. V. Sychev
A. V. Sychev
TST. V. Sharf
T. V. Sharf
VMV. P. Masenko
V. P. Masenko
ASA. A. Skvortsov
A. A. Skvortsov
Aim To study the effectiveness of a treatment based on monitoring the soluble ST2 receptor (sST2) concentration in patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction (LVEF) after acute decompensated heart failure (ADHF). Material and methods The study included 37 patients hospitalized for ADHF with LVEF ≤40% and sST2 concentration ≥37.8 ng/ml at the time of discharge from the hospital. Patients were randomized into two groups: a sST2 monitoring (sST2M) group (19 patients) and a standard therapy (ST) group (18 patients). The follow-up period was 12 months. At baseline, the groups practically did not differ by clinical, functional, laboratory, and instrumental characteristics. For the sST2M group, the goal was reducing the sST2 concentration by >30% of baseline or to <30 ng/ml. Results Therapy in both groups was comparable both in doses and in frequency of administration of basic drugs. However, the diuretic therapy was more frequently adjusted in the sST2M group (3.0 [1.0; 4.0] vs. 1.0 [0; 3.0] adjustments per patient, p = 0.047), which required more visits to the clinic (7.0 [6.0; 9.0] vs. 6.0 [6.0; 6.0] visits per patient, p=0.024). In the sST2M group at 6 months, the sST2 concentration was decreased by 43.3% (p=0.001), and 13 patients (72.2%) achieved the goal. In the ST group, the sST2 concentration was decreased by 38.5% (p=0.001), and 11 patients (68.8%) reached the target values. After 12 months, the downward trend continued in both groups. In both groups, the NT-proBNP concentration decreased: in the sST2M group by 27.7% (p=0.014), and in the ST group by 31.9% (p = 0.006). By the 12th month, the decrease remained only in the sST2M group. Only the sST2M group had an increase in LVEF (+28.5%, p=0.003), a decrease in left ventricular end-systolic volume (LVESV) (-12.0%, p=0.017), and a decrease in left atrial volume (-13.4%, p=0.045); at 12 months, LVEF remained increased (26%, p=0.006), and LA volume remained decreased (-14.3%, p=0.028). Quality of life and results of 6-minute walk test (6MWT) improved in both groups. For 6 months of treatment, the sST2M group had a significantly lower incidence of composite endpoints (CEP, cardiovascular death and decompensation/hospitalization due to HF), 26.3% (5 events) of the sST2M group compared to the ST group, 83.3% (15 events) (p=0.029), primarily due to a lower incidence of decompensated HF. For 12 months of follow-up, the incidence of CEP in the ST group was 122.2% (22 events), and 47.4% (9 events) in the sST2M group (p=0.035). Conclusions   The tactics of sST2 monitoring used in the treatment of “high-risk” HFrEF patients (with high sST2 concentrations) is associated with increased LVEF, improved functional status of patients, a beneficial effect on LV remodeling, and decreased incidence of CEP.

11 December 2020 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
МММ.д. Муксинова
М.д. Муксинова
ОНО.ю. Нарусов
О.ю. Нарусов
АСА.в. Сычев
А.в. Сычев
ТШТ.в. Шарф
Т.в. Шарф
СТС.н. Терещенко
С.н. Терещенко
АСА.а. Скворцов
А.а. Скворцов
В статье приведены два клинических примера лечения пациентов после перенесенной острой декомпенсации сердечной недостаточности с использованием мониторирования концентрации нового биомаркера сердечной недостаточности (СН) — растворимого sST2-рецептора. Обсуждены преимущества этого биомаркера перед натрийуретическими пептидами, которые позволили достичь успеха в лечении пациентов с СН высокого риска In article presents 2 clinical cases of patient’s treatment after acute decompensated heart failure using concentration monitoring of a new biomarker of heart failure — soluble ST2-receptor. The advantages of this biomarker over natriuretic peptides, which allowed to achieve success in the treatment of patients with high risk HF, were discussed